Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson’s Disease
/PRNewswire/ — Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced that the World…
March 12, 2026